SREBP1 regulates tumorigenesis and prognosis of pancreatic cancer through targeting lipid metabolism

Tumor Biology

Volumn 36, Issue 6, 2015, Pages 4133-4141

  Sun, Yan ^a   He, Weiwei ^b   Luo, Man ^a   Zhou, Yuhong ^a   Chang, Guilin ^a   Ren, Weiying ^a   Wu, Kefen ^a   Li, Xi ^a   Shen, Jiping ^a   Zhao, Xiaoping ^b   Hu, Yu ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Lipid metabolism; Pancreatic cancer; Prognosis; SREBP1

Indexed keywords

STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TUMOR MARKER; SREBF1 PROTEIN, HUMAN;

ACC GENE; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER INHIBITION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; FASN GENE; FEMALE; GENE; GENE REPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LIPID METABOLISM; LIPOGENESIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PANCREAS CARCINOGENESIS; PANCREAS CARCINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCD1 GENE; VERY ELDERLY; ANIMAL; BIOSYNTHESIS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

AGED; ANIMALS; APOPTOSIS; CARCINOGENESIS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPID METABOLISM; LIPOGENESIS; MALE; MICE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938972141     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3047-5     Document Type: Article

References (28)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30. doi:10.3322/caac.21166.
2. Klapman J, Malafa MP. Early detection of pancreatic cancer: why, who, and how to screen. Cancer Control. 2008;15(4):280–7.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.
4. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21(3):297–308. doi:10.1016/j.ccr.2012.02.014.
5. Tennant DA, Duran RV, Gottlieb E. Targeting metabolic transformation for cancer therapy. Nat Rev Cancer. 2010;10(4):267–77. doi:10.1038/nrc2817.
6. Sun Y, Zhao X, Zhou Y, Hu Y. miR-124, miR-137 and miR-340 regulate colorectal cancer growth via inhibition of the Warburg effect. Oncol Rep. 2012;28(4):1346–52. doi:10.3892/or.2012.1958.
7. Sun Y, Zhao X, Luo M, Zhou Y, Ren W, Wu K, et al. The pro-apoptotic role of the regulatory feedback loop between miR-124 and PKM1/HNF4alpha in colorectal cancer cells. Int J Mol Sci. 2014;15(3):4318–32. doi:10.3390/ijms15034318.
8. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7(10):763–77. doi:10.1038/nrc2222.
9. Walter K, Hong SM, Nyhan S, Canto M, Fedarko N, Klein A, et al. Serum fatty acid synthase as a marker of pancreatic neoplasia. Cancer Epidemiol Biomarkers Prev. 2009;18(9):2380–5. doi:10.1158/1055-9965.EPI-09-0144.
10. Zhao X, Feng D, Wang Q, Abdulla A, Xie XJ, Zhou J, et al. Regulation of lipogenesis by cyclin-dependent kinase 8-mediated control of SREBP-1. J Clin Invest. 2012;122(7):2417–27. doi:10.1172/JCI61462.
11. Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 2012;148(1–2):244–58. doi:10.1016/j.cell.2011.12.017.
12. Yang F, Vought BW, Satterlee JS, Walker AK, Jim Sun ZY, Watts JL, et al. An ARC/mediator subunit required for SREBP control of cholesterol and lipid homeostasis. Nature. 2006;442(7103):700–4. doi:10.1038/nature04942.
13. Walker AK, Jacobs RL, Watts JL, Rottiers V, Jiang K, Finnegan DM, et al. A conserved SREBP-1/phosphatidylcholine feedback circuit regulates lipogenesis in metazoans. Cell. 2011;147(4):840–52. doi:10.1016/j.cell.2011.09.045.
14. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109(9):1125–31. doi:10.1172/JCI15593.
15. Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, et al. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. Cell Metab. 2008;8(3):224–36. doi:10.1016/j.cmet.2008.07.007.
16. Guo D, Bell EH, Chakravarti A. Lipid metabolism emerges as a promising target for malignant glioma therapy. CNS Oncol. 2013;2(3):289–99. doi:10.2217/cns.13.20.
17. Huang WC, Li X, Liu J, Lin J, Chung LW. Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res. 2012;10(1):133–42. doi:10.1158/1541-7786.MCR-11-0206.
18. Ettinger SL, Sobel R, Whitmore TG, Akbari M, Bradley DR, Gleave ME, et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res. 2004;64(6):2212–21.
19. Li W, Tai Y, Zhou J, Gu W, Bai Z, Zhou T, et al. Repression of endometrial tumor growth by targeting SREBP1 and lipogenesis. Cell Cycle. 2012;11(12):2348–58. doi:10.4161/cc.20811.
20. Sun Y, Zhao X, Yao Y, Qi X, Yuan Y, Hu Y. Connexin 43 interacts with Bax to regulate apoptosis of pancreatic cancer through a gap junction-independent pathway. Int J Oncol. 2012;41(3):941–8. doi:10.3892/ijo.2012.1524.
21. Zhao X, Xiaoli, Zong H, Abdulla A, Yang ES, Ji JY, et al. Inhibition of SREBP transcriptional activity by a boron-containing compound improves lipid homeostasis in diet-induced obesity. Diabetes. 2014. doi:10.2337/db13-0835.
22. Griffiths B, Lewis CA, Bensaad K, Ros S, Zhang Q, Ferber EC, et al. Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Cancer Metab. 2013;1(1):3. doi:10.1186/2049-3002-1-3.
23. Mashima T, Seimiya H, Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer. 2009;100(9):1369–72. doi:10.1038/sj.bjc.6605007.
24. Ameer F, Scandiuzzi L, Hasnain S, Kalbacher H, Zaidi N. De novo lipogenesis in health and disease. Metabolism. 2014;63(7):895–902. doi:10.1016/j.metabol.2014.04.003.
25. Calvisi DF, Wang C, Ho C, Ladu S, Lee SA, Mattu S, et al. Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. Gastroenterology. 2011;140(3):1071–83. doi:10.1053/j.gastro.2010.12.006.
26. Yamashita T, Honda M, Takatori H, Nishino R, Minato H, Takamura H, et al. Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J Hepatol. 2009;50(1):100–10. doi:10.1016/j.jhep.2008.07.036.
27. Israel M, Schwartz L. The metabolic advantage of tumor cells. Mol Cancer. 2011;10:70. doi:10.1186/1476-4598-10-70.
28. Swierczynski J, Hebanowska A, Sledzinski T. Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer. World J Gastroenterol. 2014;20(9):2279–303. doi:10.3748/wjg.v20.i9.2279.